Which companies are Harbin Medisan Pharmaceutical's closest peers?

The cockpit's peer set: Evonile Pharma (EVONILE.NS), Shaanxi Kanghui Pharmaceutical Co (603139.SS), Teyi Pharmaceutical (002728.SZ), Shanghai Jiaoda Onlly (600530.SS), Zhuhai Rundu Pharmaceutical (002923.SZ), Zhejiang Huakang Pharmaceutical (605077.SS), Kexing Biopharm (688136.SS), Zhejiang Chengyi Pharmaceutical (603811.SS).

Is Harbin Medisan Pharmaceutical expensive compared with its peers?

On ev / sales it trades at 4.5× against a peer median of 4.0×, 10th most expensive of 21 in its peer set.

How has Harbin Medisan Pharmaceutical stock performed?

Over six months to 6 Nov 2026 the shares returned -13.1% against -19.7% for the median peer; over one year -28.9%.

← CockpitCompetitor Analysis › 002900.SZ Harbin Medisan Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Harbin Medisan Pharmaceutical Co., Ltd. Class A002900.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Momentum weak 35

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$467M

US dollars, full cap

Free float

76%

of shares outstanding

$/day

$13.7M

20-day average traded

Fwd P/E

n/m

no positive forecast

ROIC−WACC

-10.5 pp

WACC 6.5%

Hurdle

n/a

no reverse DCF

Close · CNYCN¥10.05

1D-2.1%

1W+2.1%

1M-21.4%

3M-10.8%

6M-13.1%

YTD-19.3%

1Y-28.9%

ATR %5.6%

52w lowhigh41.5% off high

What Harbin Medisan Pharmaceutical does

Employees: 2,086

Harbin Medisan Pharmaceutical at a glance

Size Harbin Medisan Pharmaceutical (002900.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $467M, the 4030th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥10.05 on 6 Nov 2026.

Performance Over six months the shares fell 13.1%, against -19.7% for the median peer and -16.4% for the China market (cap-weighted) — 9th highest of 20 in its peer set.

Growth Revenue fell 4.5% over the last twelve months (peer median -3.1%); the operating margin is -28.7% (peer median 3.3%).

Valuation It trades at 4.5× enterprise value to sales against a peer median of 4.0× (10th most expensive of 21).

Capital Return on invested capital runs 10.5 points below its cost of capital (6.5% WACC).

Relative performance

Six months, rebased to 100: Harbin Medisan Pharmaceutical against the median of its 20 peers (local-currency closes).

Harbin Medisan Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	CN¥832M	CN¥787M	CN¥1.12B	CN¥1.18B	CN¥1.02B
Revenue growth	—	-30%	-5%	+16%	—
Gross profit	CN¥361M	CN¥244M	CN¥528M	CN¥660M	CN¥606M
EBITDA	n/a	-CN¥204M	CN¥149M	CN¥106M	CN¥78.3M
Net income	-CN¥225M	-CN¥340M	CN¥58.7M	CN¥73.7M	CN¥30.2M
Free cash flow	-CN¥118M	-CN¥255M	-CN¥295M	-CN¥256M	CN¥63.6M
Capital expenditure	CN¥158M	CN¥248M	CN¥346M	CN¥300M	CN¥89.2M
Total debt	CN¥980M	CN¥1.14B	CN¥1.06B	CN¥802M	CN¥744M

Quarterly statements and history in the cockpit →

Harbin Medisan Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Harbin Medisan Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Harbin Medisan Pharmaceutical is the large dot.

Harbin Medisan Pharmaceutical competitors and peer comparison

How Harbin Medisan Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Harbin Medisan Pharmaceutical against its 20 peers (data as of 6 Nov 2026)
Measure	002900.SZ	Peer median	Rank in peer set
1-month return	-21.4%	-11.3%	4th lowest of 20
6-month return	-13.1%	-19.7%	9th highest of 20
Distance from 52-week high	-41.5%	-40.7%	10th lowest of 20
Revenue growth (TTM)	-4.5%	-3.1%	10th lowest of 21
Operating margin	-28.7%	3.3%	6th lowest of 21
EV / Sales	4.5×	4.0×	10th most expensive of 21
ROIC minus cost of capital	-10.5 pp	-2.5 pp	4th lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g	Delivered g
Harbin Medisan Pharmaceutical 002900.SZ	China	$467M	-13%	-5%	-29%	4.5×	n/a	n/a
Evonile Pharma EVONILE.NS	India	$466M	n/a	-5%	12%	14.5×	46.5%	-1.5%
Shaanxi Kanghui Pharmaceutical Co 603139.SS	China	$466M	-20%	-21%	-68%	9.0×	n/a	n/a
Teyi Pharmaceutical 002728.SZ	China	$465M	-9%	-7%	7%	3.5×	26.6%	+8.0%
Shanghai Jiaoda Onlly 600530.SS	China	$464M	-22%	-2%	-2%	10.4×	33.5%	-0.9%
Zhuhai Rundu Pharmaceutical 002923.SZ	China	$464M	-30%	+14%	5%	2.4×	2.5%	-1.3%
Zhejiang Huakang Pharmaceutical 605077.SS	China	$470M	-39%	+35%	4%	1.2×	n/a	n/a
Kexing Biopharm 688136.SS	China	$470M	-38%	-14%	-12%	3.1×	n/a	n/a
Zhejiang Chengyi Pharmaceutical 603811.SS	China	$463M	-21%	+7%	19%	3.6×	7.1%	+1.3%
Cachet Pharmaceutical 002462.SZ	China	$471M	-22%	-14%	0%	0.2×	-8.9%	-3.4%
YungShin Global 3705.TW	Taiwan	$474M	+7%	-8%	15%	1.9×	-4.9%	+0.7%
Pulike Biological Engineering 603566.SS	China	$475M	-22%	-9%	5%	2.5×	5.7%	+3.3%
Jiangsu Sihuan Bioengineering 000518.SZ	China	$476M	+7%	-17%	-28%	11.5×	n/a	n/a
Hainan Shuangcheng Pharmaceuticals 002693.SZ	China	$476M	-10%	+40%	13%	11.1×	44.5%	+1.0%
Elixiron Immunotherapeutics (Cayman) 7871.TWO	Taiwan	$477M	+62%	+10,947%	-194%	132.2×	n/a	n/a
CytomX Therapeutics CTMX	United States	$477M	-45%	-87%	-477%	8.3×	n/a	n/a
Beijing Foyou Pharma 601089.SS	China	$455M	-24%	+5%	10%	0.2×	n/a	n/a
Gufic Biosciences GUFICBIO.NS	India	$454M	+44%	+17%	14%	4.4×	n/a	n/a
Aquestive Therapeutics AQST	United States	$454M	-16%	+13%	-114%	10.5×	n/a	n/a
Alpha Teknova TKNO	United States	$482M	+104%	+12%	-35%	11.3×	n/a	n/a
Shanghai Shenqi Pharmaceutical Investment Management 600613.SS	China	$483M	+9%	-4%	3%	1.4×	13.4%	+1.4%

Questions

Which companies are Harbin Medisan Pharmaceutical's closest peers?: The cockpit's peer set: Evonile Pharma (EVONILE.NS), Shaanxi Kanghui Pharmaceutical Co (603139.SS), Teyi Pharmaceutical (002728.SZ), Shanghai Jiaoda Onlly (600530.SS), Zhuhai Rundu Pharmaceutical (002923.SZ), Zhejiang Huakang Pharmaceutical (605077.SS), Kexing Biopharm (688136.SS), Zhejiang Chengyi Pharmaceutical (603811.SS).
Is Harbin Medisan Pharmaceutical expensive compared with its peers?: On ev / sales it trades at 4.5× against a peer median of 4.0×, 10th most expensive of 21 in its peer set.
How has Harbin Medisan Pharmaceutical stock performed?: Over six months to 6 Nov 2026 the shares returned -13.1% against -19.7% for the median peer; over one year -28.9%.